MARTHA E. MANNING - 04 Feb 2022 Form 4 Insider Report for MARINUS PHARMACEUTICALS INC

Role
VP Gen Counsel and Corp Sec.
Signature
/s/ Debra A. Mohollen, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Feb 2022
Net transactions value
$0
Form type
4
Filing time
07 Feb 2022, 15:11:58 UTC
Next filing
26 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNS Common Stock Award $0 +12,867 $0.000000 12,867 04 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNS Stock Option (Right to Buy) Award $0 +57,900 $0.000000 57,900 04 Feb 2022 Common Stock 57,900 $10.40 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on August 4, 2023, the second installment vesting on August 4, 2024, and the third installment vesting on August 4, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
F2 The option vests and becomes exercisable in 36 equal monthly installments beginning on March 4, 2022.

Remarks:

Exhibit 24: Power of Attorney